Beclin 1 expression is associated with the occurrence and development of esophageal squamous cell carcinoma

Du, Hong; Che, Jiamin; Shi, Minmin; Zhu, Liangjun; Hang, Jun Biao; Chen, Zhongyuan; Li, Hecheng

doi:10.3892/ol.2017.7015

Cited by 9 publications

(7 citation statements)

References 25 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that the expression of Beclin-1 significantly affected the number of invasive cells in EC9706 only when Bcl-2 was highly expressed. One of our previous study [ 20 ] and another study by Farkas et al [ 21 ] showed that Beclin-1 and Bcl-2 could be prognositc predictive marks in ESCC respectively. Our present study indicate that increased expression of Beclin-1 protein may reduce the invasiveness of EC9706 cells only in combination with high Bcl-2 expression levels.…”

Section: Discussionmentioning

confidence: 96%

Beclin-1 is a Promising Prognostic Biomarker in a Specific Esophageal Squamous Cell Carcinoma Population

Luo

Shi

et al. 2021

Pathol. Oncol. Res.

Self Cite

View full text Add to dashboard Cite

The effects of autophagy and apoptosis in the prognostic assessment and treatment of Esophageal squamous cell carcinoma (ESCC) remain to be elucidated. Here, we conducted a retrospective study on the histopathology of ESCC, investigated the expression of Beclin-1 and Bcl-2 proteins (both autophagy- and apoptosis-related) in esophageal cancer tissue, and analyzed the significance of these proteins for the prognosis of ESCC. In the present study, the expression level of Beclin-1 in ESCC was significantly lower than that in adjacent tissues (p < 0.01), whereas the expression level of Bcl-2 showed the opposite pattern (p < 0.01). Furthermore, low expression of Beclin-1 was associated with more advanced ESCC stages and lymph node metastasis. However, high expression of Bcl-2 was associated with more advanced ESCC stages, deeper tumor invasion, and lymph node metastasis. Moreover, the relationship between Bcl-2 expression and OS was not significant (p > 0.05), whereas Beclin-1 expression was significantly associated with OS (p < 0.05). Subgroup analysis showed that Beclin-1 expression was significantly associated with OS in the high-Bcl-2-expression group but not in the low-Bcl-2-expression group. Importantly, Beclin-1 upregulation or downregulation significantly upregulated or downregulated invasion, respectively, in EC9706 cells in combination with high expression but not low expression of Bcl-2. These findings reveal that differences in autophagy and apoptotic states and their activities may promote malignant tumor differentiation, which could lead to a more aggressive esophageal squamous cell phenotype and a worse survival prognosis. Here, Beclin-1 was shown to be a promising prognostic biomarker and therapeutic target for patients with ESCC in the high-Bcl-2-expression population.

show abstract

Section: Discussionmentioning

confidence: 96%

Beclin-1 is a Promising Prognostic Biomarker in a Specific Esophageal Squamous Cell Carcinoma Population

Luo

Shi

et al. 2021

Pathol. Oncol. Res.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Co-occurrence of ATG7 deletions with amplification in NFE2L2 [4], encoding the antioxidant mediator NRF2, support ATG7 as a critical mediator of oxidative stress [15–17]. Decreased and/or lost expression of BECLIN 1, an effector of AV nucleation, was also reported in ESCC tumors [18,19]. Complementary BECLIN 1 knockdown and overexpression experiments further revealed a respective increase and decrease in invasion of EC9706 ESCC cells, supporting a potential functional role for BECLIN 1 downregulation in ESCC progression [19].…”

Section: Expression Of Atg Genes and Proteins Is Altered In Esccmentioning

confidence: 99%

Autophagy as a cytoprotective mechanism in esophageal squamous cell carcinoma

Hall

Tétreault

Hamilton

et al. 2018

Current Opinion in Pharmacology

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is amongst the most aggressive human malignancies, representing a significant health burden worldwide. Autophagy is an evolutionarily conserved catabolic process that degrades and recycles damaged organelles and misfolded proteins to maintain cellular homeostasis. Alterations in autophagy are associated with cancer pathogenesis, including ESCC; however, the functional role of autophagy in ESCC remains elusive. Here, we discuss the clinical relevance of autophagy effectors in ESCC and review current knowledge regarding the molecular mechanisms through which autophagy contributes to ESCC. We highlight the cytoprotective role of autophagy in ESCC and discuss autophagy inhibitors as novel experimental therapeutics to potentiate the effects of anti-cancer therapies and/or to overcome therapeutic resistance in ESCC.

show abstract

“…Autophagy inhibition was achieved by the transfection of cells with Becn1 small interfering (si)RNA; knockdown in SH-SY5Y cells decreased LC3-II content, thereby suppressing cell viability (58). Reduction of Beclin-1 by siRNA resulted in defective autophagy and decreased the number of AVOs in human glioblastoma U87 and esophageal squamous cell carcinoma EC9706 cells (63,64).…”

Section: Discussionmentioning

confidence: 99%

Lidocaine induces protective autophagy in rat C6 glioma cell line

et al. 2018

View full text Add to dashboard Cite

Malignant glioma is the most common type of brain cancer with poor prognosis. Surgical resection, chemotherapy and radiotherapy are the main therapeutic options; however, in addition to their insufficient efficacy, they are associated with the pain experienced by patients. To relieve pain, local anesthetics, such as lidocaine can be used. In the present study, the effects of lidocaine on the C6 rat glioma cell line were investigated. An MTT assay and Annexin V/propidium iodide analysis indicated the increase in the percentage of apoptotic and necrotic cells in response to lidocaine. Furthermore, light microscopy analysis on the ultrastructural level presented the occurrence of vacuole-like structures associated with autophagy, which was supported by the analysis of autophagy markers (microtubule-associated protein 1A/1B-light chain 3, acridine orange and Beclin-1). Additionally, reorganization of the cytoskeleton was observed following treatment with lidocaine, which serves an important role in the course of autophagy. To determine the nature of autophagy, an inhibitor, bafilomycin A1 was applied. This compound suppressed the fusion of autophagosomes with lysosomes and increased the percentage of apoptotic cells. These results demonstrated that lidocaine may induce cytoprotective autophagy and that manipulation of this process could be an alternative therapeutic strategy in the treatment of cancer.

show abstract

Beclin 1 expression is associated with the occurrence and development of esophageal squamous cell carcinoma

Cited by 9 publications

References 25 publications

Beclin-1 is a Promising Prognostic Biomarker in a Specific Esophageal Squamous Cell Carcinoma Population

Beclin-1 is a Promising Prognostic Biomarker in a Specific Esophageal Squamous Cell Carcinoma Population

Autophagy as a cytoprotective mechanism in esophageal squamous cell carcinoma

Lidocaine induces protective autophagy in rat C6 glioma cell line

Contact Info

Product

Resources

About